Low-dose natural antimicrobial exacerbates chronic lung infection in cystic fibrosis

This shows the proposed model of LL-37 induced mutagenesis and mucoid conversion. Step Ia, at low doses LL-37 (*) interacts with Pseudomonas aeruginosa and enters bacterial cells, binding to DNA (Step Ib). LL-37/DNA interactions promote mucA mutagenesis and conversion to the mucoid phenotype (Step II). Mucoid P. aeruginosa biofilms are now more resistant to killing by lethal levels of LL-37 and are selected for in the CF pulmonary environment (Step III). Credit: Wozniak et. al

Respiratory failure caused by chronic lung infection with Pseudomonas aeruginosa bacteria is a common cause of death in patients with cystic fibrosis (CF), a genetic disease that is common in individuals of European descent. A study published on April 24th in PLOS Pathogens demonstrates that an antimicrobial peptide produced by human immune cells can promote mutations in the bacterium that make it more lethal.

Daniel Wozniak, from The Ohio State University Wexner Medical Center, USA, and colleagues studied a process called "mucoid conversion", which involves mutations in Pseudomonas that produce a sticky sugar coating of the which makes them more resistant to various treatments. The process is fairly well understood, and involves mutation of a particular Pseudomonas gene called mucA. Searching for factors of the human host that facilitate mucA mutation, the scientists found that specific called polymorphonucleocytes (or neutrophils), which are present in large numbers in lung of patients with CF, can trigger Pseudomonas mucoid conversion, and that a specific antimicrobial factor produced by these cells called LL-37 plays a key role.

At high doses, LL-37 can kill bacteria by poking large holes into their cell walls. However, at lower concentrations (which seem to mimic the situation in the lungs of CF patients), the scientists found that some LL-37 molecules can enter the bacterial cells without killing them. Once inside, LL-37 appears to be able to directly interact with and alter the bacterial DNA, leading to mutation of the mucA gene. The resulting mucoid conversion makes the sugar-coated bacteria then resistant to higher doses of LL-37, including doses that would readily kill the "naked" Pseudomonas bacteria prior to mucoid conversion.

The scientists went on to show that LL-37 can induce mutations besides those in mucA in both Pseudomonas and E. coli, showing that its function as a mutagen is neither restricted to a particular gene nor a particular pathogen.

Taken together, the results demonstrate that an antimicrobial substance can, at low dose, function as a mutagen that makes bacteria more dangerous. Given that similar to LL-37 are being discussed as promising leads for the development of new antibiotics, the scientists say their data "reinforce how important it is to consider the impact of current and novel treatments and the host immune response on evolution of microbial communities during chronic infections."

More information: Limoli DH, Rockel AB, Host KM, Jha A, Kopp BT, et al. (2014) Cationic Antimicrobial Peptides Promote Microbial Mutagenesis and Pathoadaptation in Chronic Infections. PLoS Pathog 10(4): e1004083. DOI: 10.1371/journal.ppat.1004083

add to favorites email to friend print save as pdf

Related Stories

Bacteria communicate to help each other resist antibiotics

Jul 03, 2013

New research from Western University unravels a novel means of communication that allows bacteria such as Burkholderia cenocepacia (B. cenocepacia) to resist antibiotic treatment. B. cenocepacia is an environmental bacter ...

Bacterial food web may be key to cystic fibrosis

Jan 13, 2014

(Medical Xpress)—Cystic fibrosis patients suffer from chronic bacterial infections and thick mucous in their lungs, due largely to a combination of microbial infections and resulting inflammation. A common pathogen, Pseudomonas ...

Exploring a microbial arms race

Apr 07, 2014

A rapid evolutionary "arms race" between bacteria and the killer viruses they contain has been observed by a UNSW-led team of scientists in a sophisticated genetic study of the micro-organisms.

Sorting good bacteria from bad

Nov 19, 2013

An international team engineers and biologists has developed a new technique that could lead to improved infection diagnosis for cystic fibrosis patients.

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments